var data={"title":"Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A2","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - A2</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-a2/contributors\" class=\"contributor contributor_credentials\">Lloyd Axelrod, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-a2/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 22, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">ANSWER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Correct.</p><p>The patient and allergist report that the patient requires systemic steroids for several months each year during the allergy season and will be on <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> for the next three to four months, probably at a dose of 20 to 30 mg a day in the morning.</p><p>The management of glucocorticoid-induced hyperglycemia depends, in part, on the anticipated duration of glucocorticoid therapy. If the anticipated course is brief (as an example, one to two weeks), it may be sufficient to increase the doses of short-acting or very-short-acting insulin and to avoid a change in the dose of the basal (intermediate or long-acting) insulin, the effect of which will be difficult or impossible to assess when the insulin requirement is falling as the steroid is tapered. If the anticipated dose is longer, it is helpful to increase the basal insulin dose as well.</p><p>What is your plan now?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>You increase the dose of NPH insulin to 20 units before breakfast and 10 units at bedtime. You add to the current doses of <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">regular insulin</a> before breakfast and supper an insulin correction factor before meals and at bedtime using a generous correction factor of 20, ie, 1 unit of short-acting (regular) insulin for every 20 <span class=\"nowrap\">mg/dL</span> (1.1 <span class=\"nowrap\">mmol/L)</span> elevation of the blood glucose level above a reference point of 120 <span class=\"nowrap\">mg/dL</span> (6.7 <span class=\"nowrap\">mmol/L),</span> approximately twice the correction factor one might otherwise use. (Based on the patient's insulin doses before the start of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> and using the rule of 1500, the correction factor would otherwise be 39.5.) An approach to estimating the dose of short- and very short-acting insulins is discussed separately (see <a href=\"topic.htm?path=interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2\" class=\"medical medical_answer\">&quot;Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2&quot;</a>). You anticipate further adjustment of the new insulin regimen as the patient monitors the blood glucose values on it and as the dose of prednisone is tapered. (See <a href=\"topic.htm?path=interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-b1\" class=\"medical medical_answer\">&quot;Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - B1&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>You increase the dose of NPH insulin to 20 units before breakfast and do not change the dose of NPH at bedtime. You add to the current doses of <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">regular insulin</a> before breakfast and supper an insulin correction factor before breakfast and lunch using a generous correction factor of 20, ie, 1 unit of short-acting insulin (regular in this case) for every 20 <span class=\"nowrap\">mg/dL</span> (1.1 <span class=\"nowrap\">mmol/L)</span> elevation of the blood glucose level above a reference point of 120 <span class=\"nowrap\">mg/dL</span> (6.7 <span class=\"nowrap\">mmol/L),</span> approximately twice the correction factor one might otherwise use. (Based on the patient's insulin doses before the start of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> and using the rule of 1500, the correction factor would otherwise be 39.5.) An approach to estimating the dose of short- and very-short-acting insulins is discussed separately (see <a href=\"topic.htm?path=interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2\" class=\"medical medical_answer\">&quot;Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2&quot;</a>). You anticipate further adjustment of the new insulin regimen as the patient monitors the blood glucose values on it and as the dose of prednisone is tapered. (See <a href=\"topic.htm?path=interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-b2\" class=\"medical medical_answer\">&quot;Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - B2&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>You change the insulin regimen to glargine insulin 20 units at bedtime and lispro insulin. You substitute lispro insulin for <a href=\"topic.htm?path=insulin-regular-drug-information\" class=\"drug drug_general\">regular insulin</a> before meals. You add to these doses of very-short-acting insulin an insulin correction factor before meals and at bedtime using a generous correction factor of 20, ie, 1 unit of very-short-acting insulin (lispro in this case) for every 20 <span class=\"nowrap\">mg/dL</span> (1.1 <span class=\"nowrap\">mmol/L)</span> elevation of the blood glucose level above a reference point of 120 <span class=\"nowrap\">mg/dL</span> (6.7 <span class=\"nowrap\">mmol/L),</span> approximately twice the correction factor one might otherwise use. (Based on the patient's insulin doses before the start of <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>, and using the rule of 1500, the correction factor would otherwise be 39.5.) An approach to estimating the dose of short- and very short-acting insulins is discussed separately (see <a href=\"topic.htm?path=interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2\" class=\"medical medical_answer\">&quot;Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2&quot;</a>). You anticipate further adjustment of the new insulin regimen as the patient monitors the blood glucose values on it and as the dose of prednisone is tapered. (See <a href=\"topic.htm?path=interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-b3\" class=\"medical medical_answer\">&quot;Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - B3&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 4159 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H1\" id=\"outline-link-H1\">ANSWER</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-3-hypoglycemia-in-a-patient-with-type-1-diabetes-b2\" class=\"medical medical_answer\">Interactive diabetes case 3: Hypoglycemia in a patient with type 1 diabetes - B2</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-b1\" class=\"medical medical_answer\">Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - B1</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-b2\" class=\"medical medical_answer\">Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - B2</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interactive-diabetes-case-9-management-of-type-1-diabetes-in-a-patient-on-glucocorticoid-therapy-b3\" class=\"medical medical_answer\">Interactive diabetes case 9: Management of type 1 diabetes in a patient on glucocorticoid therapy - B3</a></li></ul></div></div>","javascript":null}